A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy

Overview

The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe asthmatics who have ongoing persistent asthma symptoms despite on moderate to high doses of inhaled corticosteroids (ICS). Associations will be assessed between the types of sputum inflammatory markers and the patient's atopic status and level of asthma control as indicated by the following measures: 1. pulmonary function test (PFT) 2. asthma symptoms based on the Asthma Control Test (ACT)

Full Title of Study: “A Description of Inflammatory Cell Types in Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy (Xolair)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2009

Detailed Description

Objectives: Primary: Describe inflammatory cell types in study patients and compare changes in inflammatory cell patterns before and during anti-IgE therapy. Secondary:Describe patterns of sputum eosinophilia and neutrophilia in relation to asthma symptom improvement based on ACT and PFT Hypotheses: Differences in inflammatory response after the addition of anti-IgE therapy can be described in neutrophilic, eosinophilic and neutrophilic/eosinophilic asthmatics. Neutrophilic asthmatics patients will fail to respond when placed on anti-IgE while eosinophilic asthmatics will respond well. Sputum inflammatory markers are sensitive markers of inflammation and can predict response to new asthma treatment modalities such as anti-IgE therapy.

Interventions

  • Drug: ANTI-IGE THERAPY (XOLAIR)
    • Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.

Arms, Groups and Cohorts

  • Experimental: all patients received Xolair/active drug
    • One arm:active drug

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants With Change in Sputum Markers by End of Study
    • Time Frame: 32 weeks
    • sputum markers were classified as eosinophilic or non eosinophilic

Secondary Measures

  • Number of Participants With Response to Therapy Based on Clinical Parameters Such as ED Visits, Hospitalizations, Systemic Steroid Use and Symptom Control
    • Time Frame: 32 weeks
  • Number Participants for Whom Sputum Induction Was Safe
    • Time Frame: every 4 weeks up to 32 weeks
    • safety was assessed by measuring FEV1 levels before and after sputum induction; induction was considered safe if FEV1 levels remained the same or improved

Participating in This Clinical Trial

Inclusion Criteria

  • Moderate to severe allergic asthma, uncontrolled on conventional therapy Exclusion Criteria:

  • History of systemic illness, currently on other immune modulators like immunotherapy, IVIg – Pregnancy – IgE level >1300

Gender Eligibility: All

Minimum Age: 8 Years

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Children’s Hospital of The King’s Daughters
  • Collaborator
    • Novartis
  • Provider of Information About this Clinical Study
    • Principal Investigator: MARIPAZ B. MORALES MD, MD – Children’s Hospital of The King’s Daughters
  • Overall Official(s)
    • MARIPAZ B MORALES, MD, Principal Investigator, CHILDREN’S HOSPITAL OF KING’S DAUGHTERS/EASTERN VIRGINIA MEDICAL SCHOOL

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.